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Abstract
Introduction—Screening for specific sexually transmitted diseases (STDs) during pregnancy has 
been a longstanding public health recommendation. Prior studies have described associations 
between these infections and socioeconomic factors such as race/ethnicity and education.
Objectives—We evaluated the prevalence of STDs and the correlation socioeconomic factors 
have with the presence of these infections among pregnant women in the United States.
Methods—We conducted an analysis using self-reported data from 12,948 recently pregnant 
women from the Pregnancy Risk Assessment Monitoring System (PRAMS) in 5 states during 
2009–2011. Responses to questions about curable STDs (chlamydia, gonorrhea, syphilis, 
trichomoniasis) diagnosed during pregnancy were utilized to calculate weighted STD prevalence 
estimates and 95% confidence intervals (CI). A logistic regression was also conducted to identify 
maternal socioeconomic characteristics significantly associated with STDs; results are displayed 
as adjusted prevalence ratios (aPR). The PRAMS protocol was approved at PRAMS participating 
sites and by CDC’s Institutional Review Board.
Results—Overall, 3.3% (CI 2.9–3.7) reported ≥ 1 curable STD during her most recent 
pregnancy. The adjusted STD prevalence was higher among women with younger age (aPR, 2.4; 
CI 1.8–3.4), non-Hispanic black race/ethnicity (aPR, 3.3; CI 2.4–4.1), unmarried status (aPR, 2.1; 
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CI 1.4–3.0), no college education (aPR, 1.4; CI 1.0–1.9), annual income < $25,000 (aPR, 2.0; CI 
1.3–3.2), and no pre-pregnancy health insurance (aPR, 1.4; CI 1.1–1.8).
Conclusions for Practice—This is the largest study of prevalence of self-reported curable 
STDs among U.S. pregnant women. Differences in STD prevalence highlight the association 
between certain socioeconomic factors and the presence of STDs.
Keywords
Sexually transmitted diseases/sexually transmitted infections; Pregnant women; Socioeconomic 
factors; Pregnancy Risk Assessment Monitoring System (PRAMS)
Significance
Sexually transmitted diseases (STDs) are a substantial public health concern and prevalence 
in the general population continues to increase. Pregnant women are particularly vulnerable 
as STDs during pregnancy may result in devastating health consequences. However, little 
has been reported in the literature on the prevalence of these infections among pregnant 
women in the United States. As one of the few data sources focused on pregnant women and 
including information on STDs, the Pregnancy Risk Assessment Monitoring System 
(PRAMS) provides a unique opportunity to examine STD prevalence in this population.
Introduction
Curable sexually transmitted diseases (STDs), including chlamydia, gonorrhea, syphilis, and 
trichomoniasis, are among the most common infectious diseases in the United States, with 
chlamydia the most commonly reported notifiable disease in the nation (Centers for Disease 
Control and Prevention 2014a). According to the most current national estimates, 
approximately 1.29 million new chlamydial infections, 354,000 incident gonococcal 
infections, 680,000 new trichomonal infections, and 15,100 new syphilitic infections 
occurred among U.S. women in 2008 (Satterwhite et al. 2013). However, data regarding 
STD prevalence among U.S. pregnant women are limited, likely because of the scarcity of 
sources from which to obtain this information. For example, although chlamydia and 
gonorrhea are nationally notifiable conditions, pregnancy status may not be routinely 
reported. Additionally, some women might not be routinely screened for pregnancy when 
they present for STD screening and are not captured in STD sentinel surveillance systems. 
Other women may be appropriately screened during pregnancy but their provider may not 
report their diagnosis (Weinstock et al. 2004). Although a few studies have estimated STD 
prevalence among pregnant women in the United States, the majority of these studies are 
based on small groups (< 1400 women) or non-generalizable samples, (e.g., women 
attending STD clinics) (DiClemente et al. 2004; Johnson et al. 2011; Satterwhite et al. 2012; 
Sutton et al. 2007; Wheeler et al. 2012). Monitoring prevalence of STDs among pregnant 
women is needed because untreated STDs during pregnancy are associated with adverse 
outcomes (e.g., preterm delivery and low birth weight) that are major causes of infant 
morbidity and mortality (Andrews et al. 2000; Cotch et al. 1997; Edwards et al. 1978; Ricci 
et al. 1989). Finally, the direct cost of diagnosing and treating incident STDs in the United 
States are substantial and estimated to be $15.6 billion annually (Owusu-Edusei et al. 2013). 
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Although this estimate represents a considerable economic burden, it is a conservative one 
that does not include the costs associated with managing the adverse pregnancy outcomes 
associated with these infections (Owusu-Edusei et al. 2013).
Approximately 80–90% of chlamydial infections and 70–85% of trichomonal infections 
among women cause minimal or no symptoms (Centers for Disease Control and Prevention 
2012; Peterman et al. 2009; Sutton et al. 2007). Many women with gonorrhea are also 
asymptomatic; rates of asymptomatic gonococcal infection among women have been cited 
between approximately 50–80% (Walker and Sweet 2011; Pariser 1976). Consequently, 
these conditions often remain undiagnosed among pregnant women unless they are screened. 
National guidelines for prenatal STD screening and treatment have been established to 
reduce the burden of these infections and prevent maternal and infant complications. The 
Centers for Disease Control and Prevention (CDC), the American Congress of Obstetricians 
and Gynecologists, and the U.S. Preventive Services Task Force all recommend that 
pregnant women be screened for syphilis at the first prenatal visit (Centers for Disease 
Control and Prevention 2015b; American Academy of Pediatrics and American College of 
Obstetricians and Gynecologists 2012; U.S. Preventive Services Task Force 2017). They also 
recommend additional age- and risk-based screening for other STDs (e.g., chlamydia and 
gonorrhea) during pregnancy (American Academy of Pediatrics and American College of 
Obstetricians and Gynecologists 2012; Centers for Disease Control and Prevention 2015b; 
Meyers et al. 2008). Although routine Trichomonas vaginalis screening is not formally 
recommended for pregnant women, except among women infected with human 
immunodeficiency virus (HIV), clinicians are advised to use their discretion in deciding 
whether to screen women who are not infected with HIV (Centers for Disease Control and 
Prevention 2015b).
Multiple factors have been associated with an increased risk for acquiring STDs among 
women, including young age, black race, poverty, interpersonal violence, and limited 
education (Centers for Disease Control and Prevention 1996, 2014b; Hogben and Leichliter 
2008; Wheeler et al. 2012). However, published data are limited regarding the frequency of 
STDs and their association with these demographic and social factors among the U.S. 
pregnant population. We estimate the prevalence of self-reported curable STDs among 
pregnant women in the United States and describe the sociodemographic characteristics of 
women reporting these infections to identify characteristics that were associated with higher 
self-reported STD prevalence.
Methods
Data from the Pregnancy Risk Assessment Monitoring System (PRAMS) were used for this 
analysis. PRAMS is a U.S. population-based ongoing survey of maternal experiences and 
behaviors during pregnancy, conducted among women who have had a recent live birth. The 
survey includes questions regarding wide-ranging maternal experiences, including 
preconception and prenatal care, social support, and exposure to risk factors, among others. 
Details of the PRAMS sampling methodology have been published elsewhere, and 
information about the methodology is publically available (Centers for Disease Control and 
Prevention 2015a; Shulman et al. 2006). Briefly, the PRAMS sample of women is drawn 
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from the birth certificate files of 40 states and New York City, and each PRAMS site 
samples 1300–3400 women each year (Centers for Disease Control and Prevention 2015a). 
A standardized questionnaire is mailed to a representative sample of women 2–4 months 
after delivery, and initial nonresponders are contacted and interviewed by telephone. In 
addition to the core questions included on the surveys of every PRAMS site, each site is also 
able to customize its questionnaire by adding additional questions on such topics as STDs. 
The women’s responses are then linked to extracted birth certificate data items for analysis 
(Centers for Disease Control and Prevention 2015a). Thus, PRAMS data includes 
demographic information collected from the state’s vital records system, including age, race/
ethnicity, marital status, educational attainment, annual income, insurance status before 
pregnancy, timing of initiation of prenatal care, and the women’s experiences with intimate 
partner violence during pregnancy, among other factors (Centers for Disease Control and 
Prevention 2015a). PRAMS data are weighted at the state level to account for sampling 
stratum, nonresponses, and noncoverage, permitting population-based extrapolations. The 
PRAMS protocol was reviewed and approved at PRAMS participating sites and by CDC’s 
Institutional Review Board.
We analyzed 2009–2011 PRAMS data from the five states that included questions on STDs 
diagnosed during pregnancy (Arkansas, Delaware, Mississippi, Missouri, and New York 
State) and that obtained a minimum overall response rate of 65%, per PRAMS policy for 
data usage. Curable STDs included chlamydia, gonorrhea, syphilis, and trichomoniasis. 
Women were coded as not having a curable STD diagnosed during pregnancy if they 
reported that either no STDs were diagnosed during their most recent pregnancy or if they 
reported an STD other than chlamydia, gonorrhea, syphilis, or trichomoniasis was diagnosed 
during their most recent pregnancy. Questions regarding HIV prevalence were only asked of 
participants in one of the five sites included in this analysis, which prohibited analysis of the 
impact of this variable on STD prevalence. Therefore, HIV prevalence in this study 
population was not assessed. To calculate the prevalence of curable STDs among the study 
population, we reviewed responses to STD-related questions, which varied in the five states. 
On the Arkansas PRAMS survey, the question was “During your most recent pregnancy, did 
a doctor, nurse, or other health care worker tell you that you had any of the following 
diseases or infections?” Respondents were asked to circle either Y (Yes) or N (No) for 
chlamydia, gonorrhea, syphilis, and trichomoniasis. On the PRAMS surveys for Delaware, 
Mississippi, Missouri, and New York State, women were asked to respond to the following 
question: “During your most recent pregnancy, did a doctor, nurse, or other health care 
worker tell you that you had a sexually transmitted disease (STD),” and respondents were 
asked to check either Y (Yes) or N (No). If a woman checked Yes, she was then asked a 
follow-up question: “What infection or disease were you told that you had?” She was then 
asked to check all that apply for chlamydia, gonorrhea, syphilis, trichomoniasis, or other. If 
other was checked, she was asked to write in an answer. We excluded participants who did 
not provide a response to these STD-related questions. In addition, we omitted participants 
with missing data on other variables of interest. The maternal sociodemographic variables 
explored included age (< 25, ≥ 25 years), race/ethnicity (non-Hispanic white, non-Hispanic 
black, Hispanic, non-Hispanic other), marital status (unmarried, married), educational 
attainment (high school or less, some college), annual income (< $25,000, ≥ $25,000), 
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insurance status before pregnancy (no insurance, any insurance), timing of initiation of 
prenatal care (first trimester, after first trimester or no prenatal care), and intimate partner 
violence during the most recent pregnancy (yes, no). Because no statistically significant 
differences occurred in the prevalence of self-reported curable STDs among the non-
Hispanic white, non-Hispanic other, and Hispanic groups, the race/ethnicity variable was 
collapsed into two categories—non-Hispanic black and other. The cut-off of $25,000 was 
chosen as the break-point for the annual income variable because it was the PRAMS annual 
income level closest to the federal poverty guidelines for a family of four during the study 
years of 2009–2011 (i.e., $22,050–$22,350).
We first estimated the weighted percentage of each maternal characteristic of interest and the 
weighed prevalence and 95% confidence interval (CI) of curable STDs among the study 
population. We then estimated unadjusted prevalence ratios and their corresponding 95% CI 
to investigate the association between self-reported curable STDs diagnosed during 
pregnancy and each maternal characteristic. To further explore these associations, we 
constructed a multivariable logistic regression model using a backward selection procedure 
with statistical significance set at 0.05. The Wald F test was used to select the best fit 
between models. Adjusted prevalence and prevalence ratio estimates were calculated by 
using predicted marginals from the logistic regression model (Bieler et al. 2010). The 
descriptive portion of the analysis was performed by using SAS® 9.3 (SAS Institute, Inc., 
Cary, NC, USA), and the multivariable logistic regression analysis was performed by using 
SAS-callable SUDAAN® 11 (RTI International, Research Triangle Park, NC, USA). Data 
were weighted to account for the complex survey design, nonresponse, and noncoverage.
Results
A total of 20,268 recently pregnant women with a live birth, were sampled by the five states 
that collected data regarding curable STDs diagnosed during pregnancy during 2009–2011, 
and 13,874 (68.5%) responded to the PRAMS questionnaire. Of women responding to the 
survey, 926 (6.7%) were excluded because they did not answer questions about STDs 
diagnosed during their most recent pregnancy or due to missing covariate data (maternal 
sociodemographic variables of interest), leaving 12,948 women in the study population. The 
excluded women were more likely to be < 25 years of age (49.6% vs. 34.0%, p < 0.0001), 
non-His-panic black (21.5% vs. 14.9%, p = 0.0016), Hispanic (24.6% vs. 8.5%, p < 0.0001), 
and unmarried (54.7% vs. 41.3%, p < 0.0001). Excluded women were also more likely to 
have no college education (76.9% vs. 42.7%, p < 0.0001), to report an annual income < 
$25,000 (77.8% vs. 47.1%, p < 0.0001), and to have no health insurance before pregnancy 
(34.1% vs. 24.1%, p = 0.0002) than women in the study population.
Overall, 66.0% of the study population were aged ≥ 25 years; 14.9% were non-Hispanic 
black; and 58.7% were married (Table 1). Regarding self-reported STDs, 3.3% (CI 2.9–3.7) 
of respondents reported having had a diagnosis of one or more curable STD during their last 
pregnancy (2.4% chlamydia; 1.0% trichomoniasis; 0.5% gonorrhea; and 0.2% syphilis) 
(Table 2). Among these women with curable STDs, 86.5% reported having received a 
diagnosis of only one STD; 8.5% reported two STDs; and 5.1% reported three or more 
STDs during their last pregnancy (data not included in Table 2). Although all of the maternal 
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sociodemographic variables of interest were statistically significant in the unadjusted 
analysis, two variables (timing of initiation of prenatal care and intimate partner violence 
during pregnancy) became non-significant in the multivariable analysis and were excluded 
from the final model. Therefore, the final model included age, race/ethnicity, marital status, 
education, annual income, and insurance status before pregnancy. After controlling for each 
of these maternal sociodemographic characteristics, the adjusted prevalence of self-reported 
curable STDs was higher among women < 25 years of age compared to older women 
(adjusted prevalence ratio [aPR], 2.4; CI 1.8–3.4), among non-Hispanic black women 
compared to women of other race/ethnicities (aPR, 3.3; CI 2.4–4.1), among unmarried 
women compared to married women (aPR, 2.1; CI 1.4–3.0), and among women with no 
college education compared with women with some college education (aPR, 1.4; 95% CI 
1.0–1.9). The prevalence of self-reported curable STDs was also higher among women with 
an annual income < $25,000 compared to women with higher incomes (aPR, 2.0; CI 1.3–
3.2) and among women with no health insurance before pregnancy compared to women with 
any insurance before pregnancy (aPR, 1.4; CI 1.1–1.8) (Table 3).
Discussion
To our knowledge, this analysis is the largest study of prevalence of self-reported curable 
STDs among U.S. pregnant women. Overall, 3.3% of the study population reported having 
received a diagnosis of one or more curable STDs during their most recent pregnancy. The 
prevalence of reported STDs during pregnancy in this analysis were similar to estimates of 
STD prevalence among women from other population-based surveys (Blatt et al. 2012; 
Gottlieb et al. 2008; Sutton et al. 2007; Torrone et al. 2013, 2014). Self-reported STDs were 
substantially more common among recently pregnant women with younger age, non-
Hispanic black race/ethnicity, unmarried status, no college education, lack of health 
insurance before pregnancy and lower annual income. These results highlight the impact 
social determinants of health have on STD prevalence among pregnant women in the United 
States, a novel finding that is consistent with studies examining similar associations among 
the general population (Hogben and Leichliter 2008; Laumann and Youm 1999; Wheeler et 
al. 2012).
Our prevalence estimates are similar to findings from a previous study regarding gonorrhea 
and chlamydia positivity among pregnant women. Blatt et al. reported a 3.5% positivity rate 
for chlamydial infection and a 0.6% positivity rate for gonococcal infection among 
approximately 1.3 million pregnant women, by abstracting test result data for 2005–2008 
from a large U.S. clinical laboratory (Blatt et al. 2012). However, our prevalence estimates 
were lower than what was noted in prior studies that used either clinician-verified diagnoses 
or data from settings serving higher-risk populations (e.g., STD clinics): chlamydia (2.2–
13.8%), gonorrhea (1.2–7.1%), syphilis (1.2%), and trichomoniasis (8.9–14.9%) 
(DiClemente et al. 2004; Johnson et al. 2011; Johnson and Hellerstedt 2002; Sutton et al. 
2007; Satterwhite et al. 2012; Wheeler et al. 2012). Nevertheless, the prevalence estimates 
quoted in nearly all of these types of studies were derived from convenience samples of 
pregnant women rather than the population of all pregnant women and might not represent 
true population prevalence.
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Our findings are subject to several limitations. The most important limitation is that PRAMS 
is based on self-reported data. PRAMS does not access or collect clinical records; therefore, 
assessing screening, testing, or treatment for STDs was impossible, including whether all 
participants were screened for STDs in accordance with national recommendations for 
pregnant women. Reporting or recall bias might occur if some women were unaware of, 
misunderstood, or did not report their STD diagnoses out of reluctance to discuss this 
sensitive topic. This limitation might have resulted in prevalence underestimates. 
Conversely, women who were either symptomatic before their STD diagnoses or who had an 
adverse infant outcome might have been more likely to remember or report an STD during 
pregnancy than women receiving a diagnosis from a screening test or women with healthy 
newborns, which might bias our findings in the other direction. Although our results are 
based on self-reported data, prior studies have reported that women are able to correctly 
recall events that happened during pregnancy, even several years after the pregnancy 
(Githens et al. 1993; Liu et al. 2013b; Sou et al. 2006; Tomeo et al. 1999). Women are also 
willing to answer sensitive questions about such topics as STDs as noted in a previous study 
on maternal recall that reported 98% agreement between maternal recall and the medical 
record, when women were asked about STDs during their recent pregnancy (Githens et al. 
1993). Although not directly related to STDs, prior studies on other topics have also shown 
that self-reported data can provide reliable estimates of population prevalence (Bays et al. 
2007; Eke and Dye 2009; Soulakova et al. 2013).
These findings are not necessarily representative of the entire U.S. pregnant population. 
Although we present data from > 12,000 recently pregnant women, all participants were 
from five states, because these five were the only states that included STD questions on their 
PRAMS surveys during the study period. However, based on the 2011 U.S. census, these 
states were demographically similar to the United States overall on multiple parameters 
including the median age (38 years for the five states compared to 37.3 years for the United 
States), marital status (45.4% of females aged ≥ 15 were married compared to 46.6% for the 
United States), educational attainment (85.8% of females aged ≥ 25 were high school 
graduates versus 86.5% for the United States), median household income ($46,996 vs. 
$50,502 for the United States), poverty rate (12.8 vs. 11.7% for the United States), and lack 
of health insurance (13.9% of persons with no health insurance in the five states vs. 15.1% 
for the United States) (U.S. Census Bureau 2011). Also, PRAMS surveys women with a 
recent live birth only. Women with miscarriages or stillbirths are excluded, and prior studies 
have linked STDs to these adverse outcomes, also contributing to potential underestimates in 
our study (Baud et al. 2011; De Santis et al. 2012; Liu et al. 2013a). Although PRAMS 
collects self-reported data on HIV status during pregnancy, this question was asked of study 
participants at only one of the five states with STD-related questions on their survey. 
Consequently, we were unable to evaluate how HIV positivity might have affected the 
prevalence of curable STDs among this population, if at all. If we were able to evaluate HIV-
positive women separately, we might have observed a higher prevalence of curable STDs 
among that group, similar to prior studies (Wasserheit 1992). Furthermore, as previously 
mentioned, 926 women were excluded from the analysis because either they did not answer 
questions about STDs diagnosed during their most recent pregnancy or had missing data for 
one of the maternal sociodemographic variables of interest. These women were statistically 
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different from the study population for several parameters: age, race/ethnicity, marital status, 
educational attainment, annual income, and insurance status. As indicated, prior studies have 
noted associations between some of these social determinants of health and the presence of 
STDs among the general population, and the excluded women might have been more likely 
to report these diagnoses during their most recent pregnancy (Centers for Disease Control 
and Prevention 1996, 2014b; Hogben and Leichliter 2008; Wheeler et al. 2012). Also, 
conclusions drawn from this analysis are limited to the specific sociodemographic factors we 
assessed that might contribute to STD prevalence. We did not analyze other factors that can 
also influence STD prevalence (e.g., substance abuse or participation in high-risk sexual 
networks) (Healthy People 2020 2017). Finally, because this is a cross-sectional analysis, we 
are unable to infer causality regarding the associations we have identified.
Despite these limitations, our study expands knowledge of the frequency and demographic 
distribution of curable STDs among U.S. pregnant women, by using one of the few available 
data sources specific to this population. We report prevalence data on four common STDs 
among a population for whom surveillance has been limited and few other data are available 
in the literature. We also highlight a concern with substantial clinical, public health, and 
economic consequences and for which interventions are readily available, including 
screening, diagnostic testing, and effective treatments. Also, because PRAMS allows us to 
evaluate all pregnant women with a recent live birth, despite our sampling limitation, our 
prevalence estimates might be closer to the true prevalence of these four STDs, when 
compared with prior studies. Still, further research is warranted to address the limitations 
previously discussed. Specifically, to establish more accurate estimates, studies evaluating 
STD prevalence are needed that are inclusive of all pregnant women, regardless of the 
outcome of the pregnancy or perceived risk for infection. In addition, including pregnancy 
status on STD case reports from providers and laboratories might help facilitate more 
reliable estimates. Studies are also needed that evaluate screening and treatment of STDs 
among women during the course of prenatal care. These types of analyses can improve STD 
prevalence estimates among pregnant women and potentially create opportunities to further 
assess interactions between STDs and adverse pregnancy outcomes. Additionally, data from 
more states would strengthen representativeness. Because STDs continue to be a cause of 
morbidity among pregnant women and infants, practitioners should follow national 
screening recommendations for STDs during pregnancy.
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Table 1
Maternal characteristics of women responding to STDa questions in PRAMS—5 statesb, United States, 2009–
2011
Maternal characteristic No. (Weighted %)
Total N 12,948
Age (years)
 <25 4766 (34.0)
 ≥25 8182 (66.0)
Race/ethnicity
 Non-Hispanic black 2696 (14.9)
 Other 10,252 (85.1)
Marital status
 Married 7366 (58.7)
 Unmarried 5582 (41.3)
Education
 High school or less 6084 (42.7)
 Some college 6864 (57.3)
Annual income
 < $25,000 6675 (47.1)
 ≥$25,000 6273 (52.9)
Insurance status before pregnancy
 Any insurance 9574 (75.9)
 No insurance 3374 (24.1)
Initiation of prenatal care
 1st trimester 11,136 (89.0)
 After 1st trimester/no prenatal care 1605 (11.0)
 Missing 207
Intimate partner violence
 Yes 507 (3.3)
 No 12,394 (96.7)
 Missing 47
PRAMS Pregnancy Risk Assessment Monitoring System, STD sexually transmitted disease
a
Includes: chlamydia, gonorrhea, syphilis, trichomoniasis
bArkansas, Delaware, Missouri, Mississippi, and New York (not including New York City)
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Table 2
Self-reported STD diagnoses during pregnancy among women responding to STD questions in PRAMS—5 
statesa, United States, 2009–2011 (N = 12,948)
Criterion No. Weighted % 95% CI
No curable STDsb 12,362 96.7 96.3–97.1
Any curable STDc 586 3.3 2.9–3.7
Chlamydia 382 2.4 2.0–2.7
Trichomoniasis 214 1.0 0.8–1.2
Gonorrhea 84 0.5 0.3–0.6
Syphilis 49 0.2 0.1–0.3
CI confidence interval, PRAMS Pregnancy Risk Assessment Monitoring System, STD sexually transmitted disease
aArkansas, Delaware, Missouri, Mississippi, and New York (not including New York City)
b
Includes women who reported no STDs and women who only reported genital herpes or genital warts
c
Includes chlamydia, gonorrhea, syphilis, trichomoniasis
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Table 3
Estimated prevalences and prevalence ratios of self-reported curable STDsa during pregnancy, by maternal 
characteristic, PRAMS—5 statesb, United States, 2009–2011
Unadjusted prevalence of self- 
reported curable STDsa
N = 12,948
Unweighted % (95% CI)
PR (95% CI) Adjustedf prevalence of self- 
reported curable STDsa
N = 12,948
Unweighted % (95% CI)
aPRf (95% CI)
Age (years)
 <25 7.1 (6.1–8.2) 5.2 (3.9–6.9) 4.6 (3.9–5.5) 2.4 (1.8–3.4)
 ≥25 1.4 (1.1–1.7) Ref. 1.9 (1.5–2.5) Ref.
Race/ethnicity
 Non-Hispanic black 10.5 (8.8–12.5) 5.1 (4.0–6.5) 7.1 (5.8–8.5) 3.3 (2.4–4.1)
 Other 2.1 (1.7–2.5) Ref. 2.3 (1.9–2.7) Ref.
Marital status
 Unmarried 6.6 (5.7–7.6) 6.8 (4.9–9.4) 4.0 (3.4–4.6) 2.1 (1.4–3.0)
 Married 1.0 (0.7–1.3) Ref. 1.9 (1.4–2.6) Ref.
Education
 High school or less 5.6 (4.8–6.4) 3.4 (2.6–4.6) 3.7 (3.2–4.3) 1.4 (1.0–1.9)
 Some college 1.6 (1.3–2.1) Ref. 2.7 (2.1–3.4) Ref.
Annual income
 < $25,000 6.1 (5.4–7.0) 7.4 (5.1–10.8) 3.8 (3.3–4.4) 2.0 (1.3–3.2)
 ≥ $25,000 0.8 (0.6–1.2) Ref. 1.9 (1.3–2.9) Ref.
Insurance status before pregnancy
 No insurance 5.7 (4.7–7.0) 2.3 (1.7–2.9) 4.1 (3.4–5.1) 1.4 (1.1–1.8)
 Any insurance 2.5 (2.2–3.0) Ref. 2.9 (2.5–3.4) Ref.
Initiation of prenatal carec,d
 1st trimester 3.0 (2.6–3.4) Ref.
 After 1st trimester/no PNC 5.5 (4.1–7.4) 1.8 (1.3–2.5)
Intimate partner violencee,d
 Yes 8.2 (5.5–12.1) 2.6 (1.7–3.9)
 No 3.1 (2.8–3.6) Ref.
PR prevalence ratio, aPR adjusted prevalence ratio, CI confidence interval, PRAMS Pregnancy Risk Assessment Monitoring System, STD sexually 
transmitted disease, PNC prenatal care
a
Includes: chlamydia, gonorrhea, syphilis, trichomoniasis
bArkansas, Delaware, Missouri, Mississippi, and New York (not including New York City)
c
Excluded 207 women with missing values for the variable “Initiation of prenatal care”
d
Initiation of prenatal care and Intimate partner violence were not statistically significant in the adjusted analysis and were excluded from the final 
model
e
Excluded 47 women with missing values for the variable “Intimate partner violence”
fAdjusted for the following variables: age, race/ethnicity, marital status, education, annual income, insurance status
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